Randomized Cross Over Study Assessing the Efficacy of Non-invasive Stimulation of the Vagus Nerve in Patients With Axial Spondyloarthritis Resistant to Biotherapies: The ESNV-SPA Study Protocol

Eric Azabou1,2*, Guillaume Bao1,2, Félicie Costantino2,3,4, Madalina Jacota5, Chanez Lazizi5, Lionelle Nkam5, Martin Rottman2,6, Anne-Laure Roux2,4, Sylvain Chevallier7, Lamiae Grimaldi5 and Maxime Breban2,3,4 on behalf of the ESNV-SpA Investigators

Axial spondyloarthritis (SpA), is a major cause of chronic pain and disability that profoundly alters the quality of life of patients. Nearly half of patients with SpA usually develop drug resistance. Non-pharmacological treatments targeting inflammation are an attractive alternative to drug administration. Vagus nerve stimulation (VNS), by promoting a cholinergic anti-inflammatory reflex holds promise for treating inflammatory disease. Inflammatory reflex signaling, which is enhanced by electrically stimulating the vagus nerve, significantly reduces cytokine production and attenuates disease severity in animal models of endotoxemia, sepsis, colitis, and other preclinical models of inflammatory diseases. It has been proposed that vagal efferent fibers release acetylcholine (Ach), which can interact with α7-subunit-containing nicotinic receptors expressed by tissue macrophages and other immune cells to rapidly inhibit the synthesis/release of pro-inflammatory cytokines such as TNFα, IL-1β, IL-6, and IL-18. External vagal nerve stimulation devices are now available that do not require surgery nor implantation to non-invasively stimulate the vagal nerve. This double-blind randomized cross-over clinical trial aims to study the change in SpA disease activity, according to Assessment in Ankylosing Spondylitis 20 (ASAS20) definition, after 12 weeks of non-invasive VNS treatment vs. non-specific dummy stimulation (control...
GROUP. One hundred and twenty adult patients with drug resistant SpA, meeting the ASAS classification criteria, will be included in the study. Patients will be randomized into two parallel groups according to a cross over design: either active VNS for 12 weeks, then dummy stimulation for 12 weeks, or dummy stimulation for 12 weeks, then active VNS for 12 weeks. The two stimulation periods will be separated by a 4 weeks washout period. A transcutaneous auricular vagus nerve stimulator Tens Eco Plus SCHWA MEDICO™ France will be used in this study. The active VNS stimulation will be applied in the cymba conchae of the left ear upon the auricular branch of the vagus nerve, using low intensity (2–5 mA), once à week, during 1 h. Dummy stimulation will be performed under the same conditions and parameters as active VNS stimulation, but at an irrelevant anatomical site: the left ear lobe. This multicenter study was registered on ClinicalTrials.gov: NCT04286373.

Keywords: axial spondyloarthritis, medical device, vagus nerve, trial, protocol, neuromodulation

INTRODUCTION

Axial spondyloarthropathy (SpA) is a chronic inflammatory disease primarily affecting the sacroiliac and spinal joints that usually begins in young adults and is a major cause of chronic pain and disability that profoundly alter the quality of life of patients (Taurog et al., 2016). Its prevalence is estimated at 0.4% of the French adult population (Costantino et al., 2015). Development of anti-tumor necrosis factor (TNF) and anti-interleukin (IL)-17 biotherapies have improved the management of these patients (Braun et al., 2002). However only half of the patients respond to these treatments and many of them are only partially relieved. Moreover, these treatments are expensive and can lead to serious side effects (Braun and Sieper, 2002; Wendling and Prati, 2011; Wendling et al., 2018). Electrical stimulation of the vagus nerve (VNS) recently emerged as an alternative to effectively attenuate peripheral inflammation in a variety of pathological conditions with few side effects (Borovikova et al., 2000; Yamakawa et al., 2013; Koopman et al., 2016). VNS which has been used for decades as a treatment of drug-resistant epilepsy and depression (O’Reardon et al., 2006) is known to generate a cholinergic anti-inflammatory reflex (Huston and Tracey, 2011; Cheng et al., 2014). There is experimental evidence for the role of the vagus nerve in regulating a number of distinct important physiological pathways including cerebral blood flow (CBF), melanocortin’s, production, inflammation, glutamate excitotoxicity, norepinephrine and neurotrophic processes (Cai et al., 2014). Indeed, the vagus nerve regulates numerous central and peripheral key processes through afferent and efferent fibers (Berthoud and Neuhuber, 2000). The ascending afferent vagal nerve fibers can inform the central nervous system of the presence of peripheral inflammation (Maier et al., 1998). Anti-inflammatory reflex signaling, which is enhanced by electrically stimulating the vagus nerve, significantly reduces cytokine production and attenuates disease severity in animal models of endotoxemia (Mihaylova et al., 2012; Zhao et al., 2012), sepsis (Li et al., 2015), colitis (Meroni et al., 2018, 2019) and other preclinical models of inflammatory diseases (Li et al., 2015; Johnson et al., 2016; Ren et al., 2018; Huffman et al., 2019). The cholinergic anti-inflammatory pathways (CAP) were described by the group of KJ Tracey (Borovikova et al., 2000; Tracey, 2002; Pavlov and Tracey, 2012). Modulating the activity of the CAP has become an important therapeutic strategy for the management of inflammatory diseases (Huston, 2012; Zi et al., 2020; Wu et al., 2021). The CAP pathways innervate the spleen through the efferent vagus nerve and the splenic nerve relay, and act on macrophages by converting adrenergic stimulation into a cholinergic signal by the T cells of the spleen, which produces an anti-inflammatory effect (Hu et al., 2021).

It has been shown that vagal efferent fibers release acetylcholine (Ach), which can interact with α7-subunit-containing nicotinic receptors expressed on tissue macrophages and other immune cells to rapidly inhibit the synthesis/release of pro-inflammatory cytokines such as TNFα, IL-1β, IL-6, and IL-18 (Borovikova et al., 2000; Rosas-Ballina et al., 2008).

The anti-inflammatory properties of VNS have been extensively confirmed under experimental conditions in inflammatory pathologies like arthritis, stroke, cardiovascular diseases and lupus (Leib et al., 2013; Jiang et al., 2014; Levine et al., 2014). These findings give rise to great expectations on its use to ameliorate neuro-inflammation and to contribute to the control of the progression of infectious and inflammatory
The secondary objectives of the study are to evaluate differences in disease evolution between the active and dummy stimulation period. It has also recently been successfully evaluated in rheumatoid arthritis (RA), in patients who had failed multiple lines of anti-TNF biotherapy, with a very good tolerance and a sustained decrease of disease activity equivalent to what is observed with the most effective pharmacological treatments (Koopman et al., 2016). On the other hand, VNS modulates nociception (Randich and Gebhart, 1992). It has been demonstrated that VNS attenuates pain via immunomodulation and neuro-immune interactions involving specialized proresolving mediators such as resolvins, protectins, maresins, and lipoxins (Moisset et al., 2020; Tao et al., 2020). VNS indeed produce anti-nociceptive effects through regulation of neuroinflammation in peripheral nerves, dorsal root ganglia/trigeminal ganglia, and spinal cord/brain-through neuro-immune interactions (Lange et al., 2011; Gaul et al., 2016; Silberstein et al., 2016). These findings suggest that VNS could be a promising adjunct therapy targeting inflammatory pathways in SpA patients. This hypothesis deserves to be investigated. Implanted VNS devices have been used in humans for decades to treat refractory partial-onset seizures and severe recurrent refractory depression with confirmed safety, efficacy and only mild to moderate side effects that are predictable and shown to improve over time (Ben-Menachem, 2001; Morris et al., 2013; Ryvlin et al., 2014). Non-invasive VNS devices are now available and expected to reduce the invasiveness of the procedure and increase its acceptability (Frangos et al., 2015; Fang et al., 2017).

MAIN OBJECTIVE OF THE RESEARCH

The primary objective of this study is to evaluate the change in SpA disease activity, according to AAssessment in AS International Working Group criteria for 20% improvement criteria ASAS20 (Anderson et al., 2001) after 12 weeks of VNS treatment in comparison with dummy stimulation period.

Secondary Objectives

The secondary objectives of the study are to evaluate differences in disease evolution between the active and dummy stimulation periods of treatment, on the following parameters:

1. Change in disease activity according to “ASAS40” criteria (Sieper et al., 2009).
2. Obtaining a partial remission according to the ASAS definition.
3. Change in Bath Ankylosing Spondylitis Functional Index (BASFI).
4. Change in C-reactive protein (CRP) serum level and erythrocytes sedimentation rate (ESR).
5. Change in Ankylosing Spondylitis Disease Activity Score (ASDAS) CRP and ASDAS ESR.
6. Difference in levels of circulating cytokines: IL-6, IL-23, IL-17, IL-33, and of matrix metallopeptidases (MMP3-8-9).
7. Change in quality of life: assessment according to the following indexes: SF-36, AS Quality of Life (ASQOL) (Doward et al., 2003).
8. Change in Health Index of patient with SpA (ASAS HI) and of the Productivity at Work Index (WPI) (Kiltz et al., 2015).
9. Change in fatigue (Bath Ankylosing Spondylitis Disease Index (BASDAI) 1st question) and global pain.
10. Change in Anxiety and Depression Assessment (HAD) (Lepine et al., 1985).
11. Change in Bath Ankylosing Spondylitis Metrology Index BASMI (Jones et al., 1995).
12. Change in no-steroidal anti-inflammatory drug (NSAID) intake score (Douagos et al., 2011).

METHODS AND ANALYSIS

Participants

The current article followed the SPIRIT guidelines1 and checklist. This randomized crossover placebo-controlled double blinded multicenter clinical trial will be conducted in rheumatology departments from 16 public hospitals in France. The trial has been approved by the Ethics Committee “Comité de protection des personnes du Sud-Ouest et Outre-Mer 4” (N°IRB: IORG0009855) on October 2nd 2020. The study was registered at www.clinicaltrials.gov (NCT04286373) prior to enrollment, and is part of the SMART-VNS(TM) project, aimed at promoting research, development and technological innovation in the field of vagal neuromodulation therapy. It will be performed according to the declaration of Helsinki. Informed consent will be obtained from all participant for their participation in the study. One hundred and twenty adult SpA patients, fulfilling the ASAS classification criteria for axial SpA (Rudwaleit et al., 2009) and followed for at least 1 year, insufficiently relieved despite optimal drug management, including at least two lines of biotherapies tested for at least 6 months, will be enrolled in this study.

ELIGIBILITY CRITERIA

Inclusion Criteria

1. Adult patient (18–90 years old) meeting the ASAS classification criteria for axial SpA, followed for at least 1 year, with radiographic evidence of advanced sacro-illitis, according to modified New-York criteria (van der Linden et al., 1984) (ankylosing spondylitis) or not.
2. Patient suffering of active SpA, with or without treatment, having a total BASDAI score ≥4 (0–10) at baseline and a score of global pain ≥4 (0–10).
3. Patient insufficiently relieved despite optimal drug management for at least 6 months, including at least 2

1http://www.spirit-statement.org/
different NSAIDs at the maximum tolerated dose for at least 3 months (or less in case of intolerance) and at least two lines of biotherapies, or discontinued SpA treatments due to intolerance, contraindication.

**Exclusion Criteria**

1. Patient under guardianship.
2. Cardiac arrhythmia.
3. Patients with Cochlear implant.
4. Patients with heart implant.
5. Asthmatic patient.
6. Refusal to participate in the study or to sign the informed consent.
7. Pregnant or breastfeeding woman.
8. No affiliation to a social security scheme.
9. Previous VNS treatment.
10. Incapacity to attend the weekly appointment during the study period.

In case of skin lesion of the left ear, recruitment will be delayed until the lesion is healed.

**PROCEDURES**

**Recruitment Procedure**

This multi-center study will be conducted in Rheumatology departments from 16 Hospitals in France. The expected duration of the enrollment period is 12 months.

The screening visit will take place during a routine medical follow-up consultation in rheumatology.

The investigating physician will verify the inclusion and exclusion criteria. Eligible patients will be informed about the objectives and constraints of the study. Information note and consent form will be delivered.

After a reflection period of 1–30 days, if the patient gives his/her consent to participate to the research, patient and investigating physician will write their names on and sign the consent form at the inclusion visit. A copy of this form will be kept by the Sponsor of the study.

After obtaining the informed consent, the investigating physician will proceed to his/her enrollment in the study.

The patients who gave their written consent must be included within a month following the screening visit. The investigating physician will collect systematically the following data at the time of inclusion:

1. Demographic: date of birth, sex.
2. Main medical or surgical histories,
3. Date of diagnosis of SpA,
4. Previous lines of treatment received for SpA, including biotherapies, and their result,
5. Complementary examination results: HLA-B27 genotype, sacro-iliac joints scoring on pelvic radiograph (mandatory) and MRI (if available), as well as baseline data on SpA activity status and medication use.

Clinical and biological exams will be performed:

1. Weight and height.
2. Temperature, cardiac frequency, blood pressure.
3. Electrocardiogram.
4. Blood sample for assessment of levels of circulating cytokines: IL-6, IL-23, IL-17, IL-33, and of MMP3-8-9.

**Randomization**

In this randomized 2*2 cross-over trial, included patients will be randomized at inclusion in two groups differing by the sequence in which the treatments are to be administered: Group A: VNS active for 12 weeks, then dummy stimulation for 12 weeks; and Group B: dummy stimulation for 12 weeks then VNS active for 12 weeks. In order to maintain the blind, investigators administering the stimulation will be different from those evaluating the patients, and the latter will be blinded to the treatment administered. A centralized online randomization process will be performed and managed by the Entity responsible for monitoring the study.

Since the sites of stimulation on the left ear differ between the active and dummy periods, the patients might perceive differences between the sessions, but they will not be able to distinguish which sessions involve active VNS. Indeed, we consider that the few minor side effects that could be more frequent during the active VNS period are non-specific, rare and of little clinical importance and will not allow patients or physicians involved in endpoints assessment to identify the randomization group.

After randomization, only the investigators who apply VNS stimulation (active or dummy) will have access to the result of the randomization arm and will adapt the mode of application of the device. The staff involved in the stimulation sessions will communicate neither the type of session nor the randomization arm to the patients. Thus, patients will go to stimulation sessions without knowing whether it will be active or dummy stimulation. The physician in charge of evaluations will only receive the message that the patient has been randomized (without the result).

**Intervention and Device**

Patients randomized in group A will receive active VNS stimulation once a week for 12 weeks starting from the first week after inclusion, followed by dummy stimulation for 12 weeks.

Patients randomized to group B will receive the reverse sequence: weekly dummy stimulation for 12 weeks, followed by 12 weeks of active VNS. The two stimulation periods will be separated by a 4-weeks (± 1 week) wash-out period. Sessions are not to be performed in case of skin lesions of the left ear or other acute medical conditions preventing the patient from attending the VNS sessions.

A transcutaneous vagus nerve stimulator Tens Eco Plus SCHWA MEDICO™, France, will be used for this study. The active VNS stimulation will be applied in the hollow of the left outer ear on the auricular branch of the vagus nerve (cymba conchae), during a 1 hour session of stimulation per week, at a weak intensity value (between 2 and 5 mA) and 2 Hz.
frequency. Stimulation modalities were determined according to preliminary observation performed in a small group of refractory SpA patients that received VNS for pain treatment (Azabou E. and Breban M., unpublished data). Dummy stimulation stimulation will be performed under the same conditions and parameters as active VNS stimulation, but at an irrelevant site: the left ear lobe, according to previously published methods (Frangos et al., 2015; Fang et al., 2017). Continuous EKG signal will be monitored and recorded during all the VNS sessions in order to analyze and scope cardiac rhythm variability and vagal tone.

**Follow-up Visits**

During the first and the second treatment periods of 12 consecutive weekly stimulations, a weekly visit of each patient at the investigator site will be needed. These two periods will be separated by a 1-month washout period (see Table 1 and Figure 1).

The expected length of participation for each patient is 8 months.

Twenty-six visits are planned during the protocol, according to the following schedule:

- Treatment period 1 (TP1): The duration of the first treatment period is 12 weeks. The patients will receive a weekly treatment from the first week of TP1 (TP1_Week-1) to the 12th week (TP1_Week-12).
- Washout period (WOP): The TP1 will be followed by a 4 weeks washout period (WOP).
- Treatment period 2 (TP2): The second treatment period duration is 12 weeks, and will start after the 4 weeks' WOP. The patients will then receive a weekly treatment from the first week (TP2_Week-1) to the 12th week of the TP2 (TP2_Week-12).

**Data Collection at Endpoints**

Clinical examination including BASMI assessment: Clinical examination to collect BASMI variables will be performed at the time of baseline visit, the first week of each treatment period and at the first week following each treatment period: Baseline, TP1_Week-1, Post-TP1_Week-1; TP2_Week-1, and Post-TP2_Week-1.

Questionnaires: The questionnaires listed in the “study endpoints” will be filled in at each weekly visit during each treatment period, but also at the first week following each treatment period: TP1_Week-1, TP1_Week-2, TP1_Week-3, TP1_Week-4, TP1_Week-5, TP1_Week-6, TP1_Week-7, TP1_Week-8, TP1_Week-9, TP1_Week-10, TP1_Week-11, TP1_Week-12 and Post-TP1_Week-1; followed by TP2_Week-1, TP2_Week-2, TP2_Week-3, TP2_Week-4, TP2_Week-5, TP2_Week-6, TP2_Week-7, TP2_Week-8, TP2_Week-9, TP2_Week-10, TP2_Week-11, TP2_Week-12, and Post-TP2_Week-1. A total of 26 times of data collection.

Biological samples: Biological tests listed in the “study endpoints” section will be performed by blood sampling on a monthly basis: TP1_Week-1; TP1_Week-5; TP1_Week-9; and Post-TP1_Week-1; and TP2_Week-1; TP2_Week-5; TP2_Week-9; and Post-TP2_Week-1. A total of 8 times of data collection.

**Biological Collection Procedure**

The blood serum samples drawn for the need of the study will be transiently stored in the local biology department of each participating center during the study before being shipped to the coordinating center at the end of the study for analysis and long-term storage. The collection will be stored at −80°C at the coordinating center for a period of 10 years after the end of the study.

After completion of this study, stored samples may be used for further analysis, not described in the initial protocol but, which may be found useful in light of advances in scientific knowledge, provided the participant will be informed and will not oppose such use, as stated in the information note/consent form.

**ASSESSMENT AND MEASURES**

**Primary Endpoint**

A response according to ASAS20 definition, assessed 1 week after the end of each treatment period is the primary endpoint of this study. ASAS20 response is defined as follows: an improvement of 20% compared to baseline and an absolute improvement from baseline of at least 1 unit, in 3 of the following 4 ASAS domains: patient's global assessment, patient's assessment of pain, BASFI, and inflammation (mean of the 2 morning stiffness-related BASDAI score questions), as well as no baseline deterioration of >20% and of at least one unit in the fourth domain.

**Secondary Endpoints**

The secondary evaluation criteria for the study (collected at the end of each period) are:

1. Response according to ASAS40 definition, computed in a manner similar to that used to compute the ASAS20 response, except that it required improvement of 40% in (3 of the 4 ASAS domains, with a positive change of (2 units (on a scale of 0–10) in each domain. Absence of deterioration in the remaining domain is required and defined as for the ASAS20 response.
2. Partial remission according to the ASAS definition defined as a value of <2 units (on a scale of 0–10) in each of the 4 ASAS domains (patient's global assessment, pain, BASFI, and inflammation).
3. Change in BASFI.
4. Serum CRP level and ESR.
5. Change in ASDAS_CRP, ASDAS_ESR.
6. The level of IL-6, IL-17, IL-23, IL-33, and MMP-3-8-9.
7. SF-36, ASQOL.
8. ASAS-HI, WPI.
9. Fatigue (VAS), Global Pain (VAS).
10. HAD.
11. BASMI.
12. Change in NSAID intake score.
TABLE 1 | Organization of the ESNV-SPA study.

| Actions | Screening visit (D0) | Baseline visit (D0 ± 30 days) | Treatment period 1 (TP1 = 12 weeks) | Wash out period (4weeks) | Treatment period 2 (TP2 = 12 weeks) | 1 week after TP2 |
|---------|----------------------|-------------------------------|-----------------------------------|--------------------------|------------------------------------|-----------------|
| X       | X                    | X                             | X                                 | X                        | X                                  | X               |

Verification of inclusion and exclusion criteria

Information

Informed consent

Randomization

Medical history

Clinical examination including BASMI*

EKG

Questionnaires**

Weekly Stimulation

Blood samples*** (Biochemistry and cytokine assay)

Adverse events

*Clinical examination to collect BASMI variables will be performed at the time of baseline visit, the first week of each treatment period and at the first week following each treatment period: Baseline, TP1_Week-1, Post-TP1_Week-1; TP2_Week-1, and Post-TP2_Week-1.

**Questionnaires: The questionnaires listed in the “study endpoints” will be filled in at each weekly visit during each treatment period, but also at the first week following each treatment period: TP1_Week-1, TP1_Week-2, TP1_Week-3, TP1_Week-4, TP1_Week-5, TP1_Week-6, TP1_Week-7, TP1_Week-8, TP1_Week-9, TP1_Week-10, TP1_Week-11, TP1_Week-12, and Post-TP1_Week-1; followed by TP2_Week-1, TP2_Week-2, TP2_Week-3, TP2_Week-4, TP2_Week-5, TP2_Week-6, TP2_Week-7, TP2_Week-8, TP2_Week-9, TP2_Week-10, TP2_Week-11, TP2_Week-12, and Post-TP2_Week-1.** A total of 26 times of data collection.

Biological samples: Biological tests listed in the “study endpoints” section will be performed by blood sampling on a monthly basis: TP1_Week-1; TP1_Week-5; TP1_Week-9; and Post-TP1_Week-1; followed by TP2_Week-1, TP2_Week-2, TP2_Week-3, TP2_Week-4, TP2_Week-5, TP2_Week-6, TP2_Week-7, TP2_Week-8, TP2_Week-9, TP2_Week-10, TP2_Week-11, TP2_Week-12, and Post-TP2_Week-1. *** A total of 8 times of data collection.

Statistical Analysis

Calculation Hypotheses for the Number of Participants Required and the Result

Assuming a correlation coefficient of 0.1 for the within-patient response, 30% ASAS20 responders in the dummy stimulation period vs. 50% with active simulation, and the use of a random intercept logistic model for the statistical analysis using a 5% two-tailed threshold of significance, simulations have shown that a sample size of 90 subjects will provide 80% power for demonstrating the efficacy of active stimulation vs. placebo. Accounting for 25% potential missing values for the primary endpoint (loss to follow up, redrawn consent), we will include 120 patients in the study.

Sample Description

The characteristics of patients of each group will be described using descriptive statistics such as percentages for categorical data, means, medians, ranges and interquartile ranges for continuous variables. Groups of patients will also be described at the beginning of each period and of each treatment.

Statistical Analysis for the Primary Objective

The main statistical analysis will be performed on all randomized patients according to the Intention-To-Treat principle. A secondary analysis of the main criterion will be performed in the per protocol population comprised of patients having complied with at least 10 weeks of treatment during each treatment period, for whom all the other stipulations of the protocol have been respected and for whom all required data are available.

A subject-specific random intercept logistic model will be used to assess and test, using a 5% two-tailed threshold of significance, the effect of treatment on the percentage of ASAS20 response at the end of each period.

Statistical Analysis for the Secondary Objectives

Statistical analysis of secondary binary outcomes (i.e., response according to ASAS40 criteria and partial remission according to the ASAS definition) will be performed using similar random effect logistic models as for the primary objective. Statistical comparison between treatment periods of continuous variables (ASDAS_CRP, ASDAS_ESR, BASFI, BASMI, fatigue (BASDAI 1st question), global pain score, NSAID intake score scores, SF-36, ASQOL, ASAS HI and WPI scores, HAD, CRP serum level, ESR, levels of circulating IL-6, IL-23, IL-17, IL-33, and MMPs) will be performed using random effect linear models.

The analyses for the primary and secondary outcomes will be also performed in subgroups of patients (patients with radiographic forms of the disease and patients with non-radiographic forms of the disease), as sensitivity analyses.

All calculations will be performed using R software version 3.5.1 or later, using lme4 and lmerTest packages for the mixed effects models. Statistical tests will be performed using a Kenward-Roger method for degrees of freedom method estimation.

All statistical comparisons will be performed at the 5% level of significance.
No interim analysis is forecasted.
In case of missing data for the primary assessment criterion, no strategy of imputation is forecasted. We will take into account information available at time of last follow-up.

Quality Control and Insurance

For this Minimal Risks and Burden research study, the appropriate quality control level has been determined based on the impact and the budget of the research. Assistance Publique-Hôpitaux de Paris (AP-HP) is the sponsor of this study and, by delegation, the DRCI (Clinical Research and Innovation Department) carries out the study’s missions in accordance with Article L.1121-1 of the French Public Health Code. Assistance Publique-Hôpitaux de Paris (AP-HP) has taken out insurance with HDI–GLOBAL SE through BIOMEDIC-INSURE for the full study period, which covers its own public liability and that of any collaborator (physician or research staff), in accordance with Article L.1121-10 of the Code de la Santé Publique (French Public Health Code). A Clinical Research Associate (CRA) appointed by the sponsor will be responsible for the good completion of the study, for collecting, documenting, recording and reporting all handwritten data, in accordance with the Standard Operating Procedures applied within the Clinical Research and Innovation Department. The investigator and the members of the investigator’s team agree to make themselves available during regular Quality Control visits carried out by the Clinical Research Associate.

CONCLUSION

Current pharmacological management of inflammatory rheumatism and in particular axial SpA remains imperfect. Only 50% of patients respond to the most effective biotherapies, and many of them are only partially relieved (Braun and Sieper, 2002; Wendling and Prati, 2011). In addition, these are extremely expensive treatments that expose them to the risk of potentially serious side effects (de Koning et al., 2018; Lopez-Medina et al., 2018; Molto et al., 2018; Smolen et al., 2018; Wendling et al., 2018). The efficacy of non-invasive VNS therapy in patients with axial SpA has never been studied. This study will be the first to assess its benefit-risk balance through a rigorous randomized double-blind trial. This multi-center study includes 16 rheumatology centers in public hospitals in France, mostly university hospitals, all with good experience in conducting clinical trials. Our goal is to demonstrate the efficacy of non-invasive VNS as a treatment for axial SpA, especially in cases with resistance to biotherapies. We also expect improved quality of life and reduced short-term and long-term osteo-articular structural consequences in patients receiving VNS therapy. Proving efficacy of non-invasive VNS for reducing inflammation and its consequences in humans would open the way to clinical trials in other chronic inflammatory diseases.

CO-INVESTIGATORS

Baillet Athan, CHU de Grenoble, Grenoble (ABaillet@chu-grenoble.fr); Emmanuelle Dernis, CH le Mans, Le Mans (edernis@ch-lemans.fr); Erick Legrand, CHU d’ Angers, Angers (ErLegrand@chu-angers.fr); Marie-Christophe Boissier, Hôpital Avicenne (AP-HP), Bobigny (Marie-christophe.boissier@aphp.fr); Christian Jorgesen, CHU de Montpellier, Montpellier (christian.jorgensen@inserm.fr); Daniel Wendling, CHU de Besançon, Besançon (dwendling@chu-besancon.fr); Thierry Lequerré, CHU de Rouen, Rouen (thierry.lequerre@chu-rouen.fr); Christian Marcelli, CHU de Caen, Caen (Marcelli-c@chu-caen.fr); Jacques-Eric Gottenberg, CHU de Strasbourg, Strasbourg (jacques-eric.gottenberg@chru-strasbourg.fr); Thao PHAM, Hôpital Sainte Marguerite,
Costantino, F., Talpin, A., Said-Nahal, R., Goldberg, M., Henny, J., Chiocchia, G., et al. (2015). Prevalence of spondylitis in reference to HLA-B27 in the French population: results of the GAZEL cohort. *Ann. Rheum. Dis.* 74, 689–693. doi: 10.1136/annrheumdis-2013-204436

The trial has been approved by the Ethics Committee “Comité de protection des personnes du Sud-Ouest et Outre-Mer 4°” (NIRB: IORG0009855) on October 2nd 2020. The patients/participants provided their written informed consent to participate in this study.

**ETHICS STATEMENT**

**AUTHOR CONTRIBUTIONS**

EA and MB conceived the study. EA, GB, MB, LG, MJ, CL, MR, A-LR, FC, SC, and LN initiated the study design and helped with implementation. LG, MJ, and LN provided methodological and statistical expertise in clinical trial design. LN conducted the primary statistical analysis. All authors contributed to refinement of the study protocol and approved the final manuscript.

**REFERENCES**

Anderson, J. J., Baron, G., van der Heijde, D., Felson, D. T., and Dougados, M. (2001). Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. *Arthritis Rheum.* 44, 1876–1886. doi: 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F

Ben-Menachem, E. (2001). Vagus nerve stimulation, side effects, and long-term safety. *J. Clin. Neuropsychol.* 18, 415–418.

Berthoud, H. R., and Neuhuber, W. L. (2000). Functional and chemical anatomy of the afferent vagal system. *Auton. Neurosci.* 85, 1–17. doi: 10.1016/S1566-0702(00)00215-0

Bonaz, B., Sinniger, V., and Pellissier, S. (2017). The vagus nerve in the neuro-immune axis: implications in the pathology of the gastrointestinal tract. *Front. Immunol.* 8:1432. doi: 10.3389/fimmu.2017.01452

Borovikova, L. V., Ivanova, S., Zhang, M., Yang, H., Botchkina, G. I., Watkins, L. R., et al. (2000). Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. *Nature* 405, 458–462. doi: 10.1038/35013070

Braun, J., and Sieper, J. (2002). Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches. *Arthritis Res.* 4, 307–321. doi: 10.1186/ar592

Braun, J., Sieper, J., Breban, M., Collantes-Estevez, E., Davis, J., Inman, R., et al. (2002). Anti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experience. *Ann. Rheum. Dis.* 61(Suppl. 3), iii51–iii60. doi: 10.1136/ard.61.suppl_3.iii51

Cai, P. Y., Bodhi, A., Dereguito, R., Ansari, S., Abukhalil, F., Thenkabail, S., et al. (2014). Vagus nerve stimulation in ischemic stroke: old wine in a new bottle. *Front. Neurol.* 5:107. doi: 10.3389/fneur.2014.00107

Cheng, Z., Li-Sha, G., Jing-Lin, Z., Wen-Wu, Z., Xue-Si, C., Xing-Xing, C., et al. (2014). Protective role of the cholinergic anti-inflammatory pathway in a mouse model of viral myocarditis. *PLoS One* 9:e112719. doi: 10.1371/journal.pone.0112719

Costantino, F., Talpin, A., Said-Nahal, R., Goldberg, M., Henny, J., Chiocchia, G., et al. (2015). Prevalence of spondylitis in reference to HLA-B27 in the French population: results of the GAZEL cohort. *Ann. Rheum. Dis.* 74, 689–693. doi: 10.1136/annrheumdis-2013-204436

de Koning, A., Schooens, J. W., van der Heijde, D., and van Gaalen, F. A. (2018). Pathophysiology of axial spondyloarthritis: consensus and controversies. *Eur. J. Clin. Invest.* 48:e12913. doi: 10.1111/eci.12913

Dougados, M., Simon, P., Braun, J., Burgos-Vargas, R., Maksymowycz, W. P., Sieper, J., et al. (2011). ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. *Ann. Rheum. Dis.* 70, 249–251. doi: 10.1136/ard.2010.133488

Doward, L. C., Spoonerberg, A., Cook, S. A., Whalley, D., Hellwell, P. S., Kay, L. J., et al. (2003). Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. *Ann. Rheum. Dis.* 62, 20–26. doi: 10.1136/ard.62.1.20

Fang, J., Egorova, N., Rong, P., Liu, J., Hong, Y., Fan, Y., et al. (2017). Early cortical biomarkers of longitudinal truncutaneous vagus nerve stimulation treatment success in depression. *Neuroimage Clin.* 14, 105–111. doi: 10.1016/j.nicl.2016.12.016

Fournier, A., Mondillon, L., Dantzer, C., Gauchez, A. S., Ducros, V., Mathieu, N., et al. (2018). Emotional overactivity in patients with irritable bowel syndrome. *Neurogastroenterol. Motil.* 30:e13387. doi: 10.1111/nmm.13387

Fournier, A., Mondillon, L., Luminet, O., Canini, F., Mathieu, N., Gauchez, A. S., et al. (2020). Interceptive abilities in inflammatory bowel diseases and irritable bowel syndrome. *Front. Psychiatry* 11:229. doi: 10.3389/fpsyt.2020.00229

Fragos, E., Ellrich, J., and Komisaruk, B. R. (2015). Non-invasive access to the vagus nerve central projections via electrical stimulation of the external ear: fMRI evidence in humans. *Brain Stimul.* 8, 624–636. doi: 10.1016/j.brs.2014.11.018

Gaul, C., Diener, H. C., Silver, N., Magis, D., Reuter, U., Andersson, A., et al. (2016). Brain stimulation for chronic cluster headache (PREV A): a randomised controlled study. *Cephalalgia* 36, 534–546. doi: 10.1177/0333102415607070

Hu, J., Liu, S., and Ma, T. (2021). [Research progress of exploring the treatment of sepsis based on cholinergic anti-inflammatory pathway]. *Zhonghua Wei Zhong Bing Ji Yi Yu Xue* 33, 122–125. doi: 10.3760/cma.j.cn121430-20200421-00318

Huffman, W. J., Subramaniyan, S., Rodriguez, R. M., Wetsel, W. C., Grill, W. M., and Terrando, N. (2019). Modulation of neuroinflammation and memory dysfunction using percutaneous vagus nerve stimulation in mice. *Brain Stimul.* 12, 19–29. doi: 10.1016/j.brs.2018.10.005

The study was funded by a grant from Programme Hospitalier de Recherche Clinique—PHRC 2018 (Ministry of Health). The company SCHWA MEDICO™ supplied the medical devices needed for this research.

**ACKNOWLEDGMENTS**

We would like to thank Isabelle VIVALDO, project manager at Délégation à la Recherche Clinique et à l’Innovation, at Assistance Publique — Hôpitaux de Paris (DRCI-APHP). We also thank Frédéric LOFASO (Head of the Physiology Department), Virgina BRANCO, Anne-Claire LIBOUBAN (UVSQ), Didier LAJOIE, Mikaelle BOHIC, Marine ZAGDOUN, and Jennifer BIDOT for their helpful assistance during the initiation phase of the SMART-VNS™ project.
Huston, J. M. (2012). The vagus nerve and the inflammatory reflex: wandering on a new treatment paradigm for systemic inflammation and sepsis. Surg. Infect. 13, 187–193. doi: 10.1089/sur.2012.126

Huston, J. M., and Tracey, K. J. (2011). The pulse of inflammation: heart rate variability, the cholinergic anti-inflammatory pathway and implications for therapy. J. Intern. Med. 269, 45–53. doi:10.1111/j.1365-2796.2010.02321.x

Jiang, Y., Li, L., Liu, B., Zhang, Y., Chen, Q., and Li, C. (2014). Vagus nerve stimulation attenuates cerebral ischemia and reperfusion injury via endogenous cholinergic pathway in rat. PLoS One 9:e102342. doi: 10.1371/journal.pone.0102342

Johnson, R. L., Murray, S. T., Camacho, D. K., and Wilson, C. G. (2016). Vagal Frontiers in Human Neuroscience | www.frontiersin.org

Meroni, E., Stakenborg, N., Viola, M. F., and Boeckxstaens, G. E. (2019). Intestinal neurostimulation of the cholinergic anti-inflammatory pathway controls TNF in endotoxemia. PLoS One 9:e105328. doi: 10.1371/journal.pone.0105328

Phillips, E. C., Croft, C. L., Kurbatskaya, K., O'Neill, M. J., Hutton, M. L., Hanger, D. P., et al. (2014). Astrocytes and neuroinflammation in Alzheimer's disease. Biochem. Soc. Trans. 42, 1321–1325. doi: 10.1042/BST20140155

Randich, A., and Gebhart, G. F. (1992). Vagal afferent modulation of nociception. Brain Res. Brain Res. Rev. 17, 77–99. doi: 10.1016/0165-173X(92)90009-b

Ren, C., Li, X. H., Wu, Y., Dong, N., and Yao, Y. M. (2018). Influence of vagus nerve on multiple organ function and immune reaction of T lymphocytes in septic rats. Zhonghua Shao Shang Za Zhi. 34, 815–820. doi:10.3760/cma.j.issn.1009-2857.2018.11.018

Rosas-Ballina, M., Ochani, M., Parrish, W. R., Ochani, K., Harris, Y. T., Huston, J. M., et al. (2008). Splenic nerve is required for cholinergic antiinflammatory pathway control of TNF in endotoxemia. Proc. Natl. Acad. Sci. U.S.A. 105, 11008–11013. doi:10.1073/pnas.0803237105

Rudwaleit, M., van der Heijde, D., Landewe, R., Listing, J., Akkoc, N., Brandt, J., et al. (2009). The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann. Rheum. Dis. 68, 777–783. doi:10.1136/ard.2009.108233

Rylin, P., Gilliam, F. G., Nguyen, D. K., Collicchio, G., Iudice, A., Tinuper, P., et al. (2014). The long-term effect of vagus nerve stimulation on quality of life in patients with pharmacoresistant focal epilepsy: the PuLe18 (Open Prospective Randomized Long-term Effectiveness) trial. Epilepsia 55, 883–900. doi: 10.1111/epileps.12611

Sieper, J., Rudwaleit, M., Baraliakos, X., Brandt, J., Braun, J., Burgos-Vargas, R., et al. (2009). The assessment of spondyloarthropathies international society handbook: a guide to assess spondyloarthropathy. Ann. Rheum. Dis. 68(Suppl. 2), ii1–ii44. doi:10.1136/ard.2008.104018

Silverstein, S. D., Mchnplant, I. L., Mdnrow, B. D., Calhoun, A. H., McClure, C., Saper, J. R., et al. (2016). Non-invasive vagus nerve stimulation for the acute treatment of cluster headache: findings from the randomized, double-blind, sham-controlled ACT1 study. Headache 56, 1317–1332. doi: 10.1111/head.12896

Smolen, J. S., Schols, M., Braun, J., Dougados, M., Fitzgerald, J., Gladman, D. D., et al. (2018).Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target 2017 update of recommendations by an international task force. Ann. Rheum. Dis. 77, 3–17. doi:10.1136/annrheumdis-2017-211734

Stearo, L. Jr, Bronzuoli, M. R., Iacomino, A., Espósito, G., Steardo, L., and Scuderi, C. (2015). Does neuroinflammation turn on the flame in Alzheimer’s disease? Focus on astrocytes. Front. Neurol. 9:239. doi: 10.3389/fneur.2018.00290

Tong, T., Lee, M. S., Donnelly, C. R., and Ji, R. (2020). Neuromodulation, specialized preresolving mediators, and resolution of pain. Neurotherapeutics 17, 886–899. doi:10.1007/s13311-020-00892-9

Tuor, J. D., Chhabra, A., and Colbert, R. A. (2016). Ankylosing spondylitis and axial spondyloarthritis. N. Engl. J. Med. 375:1303. doi: 10.1056/NEJMct1609622
Tracey, K. J. (2002). The inflammatory reflex. *Nature* 420, 853–859. doi: 10.1038/1780270401

van der Linden, S., Valkenburg, H. A., and Cats, A. (1984). Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. *Arthritis Rheum.* 27, 361–368. doi: 10.1002/art.1780270401

Wendling, D., Lukas, C., Prati, C., Claudepierre, P., Gossec, L., Goupille, P., et al. (2018). 2017 Update of French Society for Rheumatology (SFR) recommendations about the everyday management of patients with spondyloarthritis. *Joint Bone Spine* 85, 275–284. doi: 10.1016/j.jbspin.2018.01.006

Wendling, D., and Prati, C. (2011). Biologic agents for treating ankylosing spondylitis: beyond TNFalpha antagonists. *Joint Bone Spine* 78, 542–544. doi: 10.1016/j.jbspin.2011.05.023

Wu, Y. J., Wang, L., Ji, C. F., Gu, S. F., Yin, Q., and Zuo, J. (2021). The role of alpha7nAChR-mediated cholinergic anti-inflammatory pathway in immune cells. *Inflammation* 44, 821–834. doi: 10.1007/s10753-020-01396-6

Yamakawa, K., Matsumoto, N., Imamura, Y., Muroya, T., Yamada, T., Nakagawa, J., et al. (2013). Electrical vagus nerve stimulation attenuates systemic inflammation and improves survival in a rat heatstroke model. *PLoS One* 8:e56728. doi: 10.1371/journal.pone.0056728

Zhao, Y. X., He, W., Jing, X. H., Liu, J. L., Rong, P. J., Ben, H., et al. (2012). Transcutaneous auricular vagus nerve stimulation protects endotoxemic rat from lipopolysaccharide-induced inflammation. *Evid. Based Complement. Alternat. Med.* 2012, 627023. doi: 10.1155/2012/627023

Zi, S., Li, J., Liu, L., and Liu, F. (2020). Cholinergic anti-inflammatory pathway and its role in treatment of sepsis. *Zhong Nan Da Xue Xue Bao Yi Xue Ban* 45, 68–73. doi: 10.11817/j.issn.1672-7347.2020.180651

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Azabou, Bao, Costantino, Jacota, Lazizi, Nkam, Rottman, Roux, Chevallier, Grimaldi and Breban. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.